742 results about "Bacterosira" patented technology

The invention relates to the technical field of microorganisms, in particular to application of pediococcus acidilactici. The pediococcus acidilactici TG005 is preserved in the China Center for Type Culture Collection on June 24, 2024, the preservation number is CCTCC NO: M 20241349, and the preservation address is Wuhan University, Wuhan, China. The pediococcus acidilactici TG005 provided by the invention is a multifunctional probiotic strain, is obtained by screening from domestic healthy human excrement samples, and has good application safety and functional adaptability; the strain can reduce the cholesterol level and prevent cardiovascular diseases; uric acid precursor substances are degraded, uric acid generation is reduced, and hyperuricemia and related diseases are prevented; pathogenic bacteria with fusobacterium nucleatum and bacteroides fragilis can be inhibited, and colorectal cancer is prevented; when being used as a probiotic additive for preparing medicines for degrading cholesterol, preventing cardiovascular diseases caused by high cholesterol, preventing hyperuricemia, colorectal cancer and the like, the lactobacillus plantarum has a wide application prospect.

The invention provides an animal bifidobacterium subsp. Lactis HNU329 with uric acid reducing ability and application thereof, the animal bifidobacterium subsp. Lactis HNU329 is preserved in Guangdong Microbiological Culture Collection Center GDMCC, the preservation address is Institute of Microbiology, Guangdong Academy of Sciences, on 5th floor, No. 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou, the preservation date is April 22, 2024, the preservation number is GDMCC No: 64546, and the preservation number is CGMCC No: 64546. The preparation method comprises the following steps of: classifying and naming Bifidobacteria animata subsp.lactis, and carrying out classification and naming on the Bifidobacteria animata subsp.lactis. The strain has good capacity of degrading nucleoside and purine in vitro, also shows good uric acid reducing capacity and anti-inflammatory capacity in animal model evaluation, and can regulate intestinal flora of mice with hyperuricemia and improve symptoms of hyperuricemia. The traditional Chinese medicine composition has no toxic or side effect, high safety and wide application prospect.

The invention relates to a method for treating nitrogen and phosphorus-containing cleaning wastewater, which comprises the following steps: adding residual activated sludge, activated carbon and a nitrogen and phosphorus removal bacterial agent into a treatment system, carrying out braising exposure treatment, and regularly adding an organic carbon source; the nitrogen and phosphorus removal bacterial agent at least contains microbacterium kitamiense (PR) and aeromicrobe (Aeromicrobe tamlense) (PW), and is characterized in that the nitrogen and phosphorus removal bacterial agent at least contains the microbacterium kitamiense (PR) and the aeromicrobe tamlense (PW); the preservation numbers of the strain are respectively CGMCC (China General Microbiological Culture Collection Center) No. 25182 and CGMCC No. Starting water feeding after braising exposure is finished, and continuously operating to treat the cleaning wastewater. According to the method, total nitrogen, total phosphorus and COD in the wastewater can be efficiently removed at the same time in one structure, the treatment burden of a subsequent biochemical unit is avoided, the process is simple, and the cost is low.

The invention discloses bifidobacterium longum subsp. Longum IMAU12449 and application thereof, belongs to the technical field of microorganisms, and provides the bifidobacterium longum subsp. Longum IMAU12449, the bifidobacterium longum subsp. Longum IMAU12449 is preserved in the China General Microbiological Culture Collection Center on July 8, 2024, the preservation address is No. 3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO. The preservation number is CGMCC (China General Microbiological Culture Collection Center) The invention provides application of the bifidobacterium longum subsp. Longum IMAU12449 in preparation of fermented cow milk and / or soybean milk. The bifidobacterium longum subsp. Longum IMAU12449 is used as a potential probiotic to prepare cow milk and soybean milk, and the prepared fermented milk is stable in viable count, moderate in acidity and free of whey precipitation.

The invention discloses a transcription factor Cgl2988 related to production of 5-aminolevulinic acid based on network model prediction and application, the amino acid sequence of the transcription factor Cgl2988 is as shown in SEQ ID NO.1. The transcription factor Cgl2988 related to production of 5-ALA is simulated and predicted based on a metabolic network model system mcCGL, and experiments prove that the transcription factor Cgl2988 related to production of 5-ALA has the advantages that the transcription factor Cgl2988 related to production of 5-ALA can be used for preparing the transcription factor Cgl2988 related to production of 5-ALA; the expression strain Cgh3-low-cgl2988 of the transcription factor gene cgl2988 in the down-regulated corynebacterium glutamicum is subjected to shake flask fermentation, and the yield of 5-ALA is 5.52 + / -0.19 g / L and is increased by about 1.64 times compared with that of a control strain; the expression strain Cgh3-pX-cgl2988 of the transcription factor gene cgl2988 in the up-regulated corynebacterium glutamicum is subjected to shake flask fermentation, and the yield of the 5-ALA is 5.76 + / -0.11 g / L, which is about 2.84 times higher than that of a control strain.

The invention provides common bacteroides and application thereof. Specifically, a strain of common bacteroides capable of producing 3-indolepropionic acid is separated from human feces for the first time, and the strain of common bacteroides is preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 25, 2025, and the preservation number is CGMCC NO.46398. The strain of common bacteroides can be used for producing 3-indolepropionic acid, and the strain of common bacteroides can be used for producing 3-indolepropionic acid. Furthermore, the invention provides an application of the common bacteroides disclosed by the invention in production of 3-indolepropionic acid. Furthermore, the invention provides a method for producing the 3-indolepropionic acid by using the common bacteroides disclosed by the invention, and an application of the common bacteroides disclosed by the invention in increasing the content of the 3-indolepropionic acid in an organism.

The invention belongs to the technical field of biological fermentation, and relates to a high-bacteriostatic-activity propionibacterium scherichia subspecies and application thereof, in particular to a propionibacterium scherichia subspecies which is classified and named as Propionibacterium fredenreichiii subsp. Scherichia CJPF0001, and the preservation number of the propionibacterium scherichia subspecies is CCTCC (China Center for Type Culture Collection) No.M 20242477. The invention further relates to a preparation method of the propionibacterium scherichia subspecies and application of the propionibacterium scherichia subspecies. The fermentation product of the strain has high protein and high bacteriostatic activity, can inhibit the growth of common spoilage microorganisms, and has the effects of improving the nutritional value of food and prolonging the shelf life of food and the like.

The invention relates to the technical field of microorganisms, and particularly discloses a fermentation method of bifidobacterium longum BBMN68 as well as a fermented product, a postbiotic and application of the fermented product. According to the method for fermenting the bifidobacterium longum BBMN68, a fermentation substrate comprises alkaline protease hydrolyzed milk and a pomelo peel extract; the hydrolysis rate of the alkaline protease hydrolyzed milk is 9-11%, and the water-soluble dietary fiber content of the shaddock peel extract is 75-80%; the mass ratio of the alkaline protease hydrolyzed milk to the shaddock peel extract is (10-15): (1-3). The content of active ingredients in the fermented product prepared by the method is high, and after the fermented product is prepared into the postbiotics to be taken, the immune function of an organism can be recovered, immune organ damage is reduced, inflammation is relieved, and intestinal flora is regulated and controlled.

The invention discloses an intestinal bacterial composition for improving a cognitive function and relieving neuroinflammation and an application of the intestinal bacterial composition, and belongs to the technical field of biomedicine and microbiology, the intestinal bacterial composition is composed of a Lachnospiraceae bacterium, a Bacteroides multiforme and a Roseburiatestinae bacterium, and the intestinal bacterial composition is prepared from the following raw materials of the following raw materials of the intestinal bacterial composition: the Lachnospiraceae bacterium, the Bacteroides multiforme and the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium and the like. Experimental research results show that a modular synergistic effect exists among the helicobacter hirsuticus, the bacteroides multiforme and the Roche enterobacter, and the pharmaceutical composition has a remarkable neuroprotective effect on a cognitive impairment mouse model and an Alzheimer disease mouse model, can improve the cognitive function and relieve neuroinflammation, and can be used for preparing a neuroprotective agent for treating the cognitive impairment mouse model and the Alzheimer disease mouse model. A new thought and method can be provided for treatment of cognitive impairment related diseases and neuroinflammation related diseases.

The invention discloses corynebacterium glutamicum for producing N-acetylglucosamine and application of the corynebacterium glutamicum, and belongs to the technical field of synthetic biology. Specifically, the corynebacterium glutamicum overexpresses a GNA1 gene from a brewer's yeast S288C controlled by a tacM promoter, a glmS gene from corynebacterium glutamicum S9114 and a yqab gene from escherichia coli K12 MG1655, and simultaneously has five gene defect types of nagA, nagB, ldhA, msccg and msccg2 in a genome and two gene single base mutation types of odhA and glnA, and the codon of the glnA for coding the 405th amino acid is mutated from TAC to TTC. By blocking excretion of glutamic acid of corynebacterium glutamicum and enhancing conversion of glutamic acid to glutamine, the supply capacity of a precursor of corynebacterium glutamicum is enhanced, and an optimal way for synthesizing N-acetylglucosamine is obtained, so that efficient production of N-acetylglucosamine in corynebacterium glutamicum is realized, and the yield of N-acetylglucosamine in corynebacterium glutamicum is increased. The method has important economic value and social significance.

The invention provides Eubacterium mucilaginosus E11405 and an application thereof. The invention provides Eubacterium mucus E11405, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the Eubacterium mucus E11405 is CGMCC No.31231. The invention further provides a preparation method of the Eubacterium mucus E11405. The inventor of the application studies the effect and mechanism of the Eubacterium mucus E11405 in relieving the mouse colorectal cancer, and the result shows that the Eubacterium mucus E11405 has a remarkable relieving effect on the mouse colorectal cancer, and can be used as a probiotic preparation for relieving the colorectal cancer. The Eubacterium mucilaginosus E11405 provides a new strategy for prevention and treatment of colorectal cancer-based digestive tract tumors, has potential clinical application prospects, and is expected to become an effective medicine for treating colorectal cancer-based digestive tract tumors.

The invention belongs to the technical field of biological medicines, and discloses a probiotic and prebiotic composition for improving intestinal microecology and assisting in resisting food allergy, and the composition comprises bifidobacterium longum and oligosaccharide in a mass ratio of (1-3): (1-3). The probiotic and oligosaccharide composition provided by the invention is clear in mechanism and wide in application range, and the effect of relieving food anaphylactic reaction is achieved by enhancing intestinal barriers and regulating intestinal flora. And under the participation of the oligosaccharide, the anti-allergic effect of the probiotics is obviously enhanced. The invention can solve the problem that the existing anti-allergic medicine treats both symptoms and root causes, simplifies the composition, defines the action mechanism of the composition, and expands the range of applicable people.

The invention discloses bifidobacterium animalis subsp. Lactis BLa65 capable of relieving constipation and regulating intestinal flora as well as application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides bifidobacterium animalis subsp. Lactis BLa65 capable of relieving constipation and regulating intestinal flora, and the preservation number of the bifidobacterium animalis subsp. Lactis BLa65 is CGMCC (China General Microbiological Culture Collection Center) No.32427. The invention also provides an application of the bifidobacterium animalis subsp. Lactis BLa65 in preparation of functional food for relaxing the bowels, and / or functional food for regulating intestinal flora, and / or a bacteriostatic agent, and / or non-treatment-destination in-vitro bacteriostasis. The BLa65 strain provided by the invention has excellent broad-spectrum antibacterial performance, a function of relieving constipation and a function of regulating intestinal flora at the same time.

The invention discloses bifidobacterium longum subsp.infantis capable of promoting bone growth and a metagen thereof, and belongs to the technical field of biology. The bifidobacterium longum subsp. Infantis CCFM1445 provided by the invention can promote the increase of bone volume fraction, femoral bone trabecula thickness and far-end growth plate thickness of mammals in a growth period, reduce the levels of serum bone resorption markers I-type collagen amino-terminal peptide and tartrate-resistant acid phosphatase, improve the levels of serum bone alkaline phosphatase and parathyroid hormone, and improve the clinical application value of the bifidobacterium longum subsp. Infantis CCFM1445. And the relative abundance of the other bacteria in the intestinal flora and the levels of creatine and indole-3-lactic acid are increased. The thermally inactivated bifidobacterium longum subsp. Infantis CCFM1445 can promote the increase of the volume fraction of femoral bones and the number of bone trabecula of malnourished mice and improve the N-terminal propeptide level of serum I-type procollagen. Therefore, the medicine or health care product prepared from the bifidobacterium longum subsp. Infantis CCFM1445 can be used for assisting in regulating bone metabolism and bone mass, and has a wide market prospect.

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis for relieving eye allergy and application of the bifidobacterium animalis. The invention provides an application of bifidobacterium animalis subsp. Lactis in preparation of a product for relieving eye allergy, the bifidobacterium animalis subsp. Lactis is Def +, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35798. The Bifidobacterium animalis subsp. Lactis Def < + > provided by the invention can relieve the eye itching symptom, relieve red and swollen eyelids, reduce conjunctiva and cornea injury, relieve eye discomfort, relieve globular conjunctivitis cell infiltration, improve corneal epithelium thickening lesion, improve the anti-inflammatory ability and improve allergic conjunctivitis, keratitis and blepharitis marginata in a targeted manner. The eye drops are high in safety and resistant to gastrointestinal fluid, and a safe and long-acting scheme is provided for eye allergic diseases.

The invention discloses three novel corynebacterium glutamicum heat-resistant elements and application thereof, and belongs to the technical field of bioengineering. Three heat-resistant genes are obtained from corynebacterium glutamicum research. The heat-resistant gene and a promoter Ptuf are connected and are combined and transformed in corynebacterium glutamicum. The heat-resistant element is introduced into a plasmid and is expressed in corynebacterium glutamicum. After 24 hours of high-temperature culture at 42 DEG C, the OD600 of the corynebacterium glutamicum containing the heat-resistant element and the plasmid is improved, and the growth condition of the corynebacterium glutamicum at 42 DEG C is obviously superior to that of the starting corynebacterium glutamicum. Therefore, the heat-resistant elements can obviously improve the heat resistance of corynebacterium glutamicum under a high-temperature culture condition. The method has important application value in improvement of the thermal stability of corynebacterium glutamicum and industrial production prospect.

The invention relates to an application of bifidobacterium breve i1088 or a postbiotic thereof in improvement of cognition. The bifidobacterium breve i1088 or the afterbiogen of the bifidobacterium breve i1088 is used for preparing a product for enhancing the oxidative stress capacity of mammalian cells, improving the in-vitro free radical scavenging level of mammals and changing at least one of the expression levels of mammalian cells Nrf2 and anti-oxidation related genes. The invention aims to explore the potential of the bifidobacterium breve in the aspect of improving the Alzheimer's disease and provide a safer and more effective nutritional supplement scheme for middle-aged and elderly people.

The invention discloses an application of an antibacterial peptide and an application of the antibacterial peptide in preparation of antibacterial drugs for treating carbapenem-resistant pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the antibacterial peptide is characterized in that the sequence is w-r-r-w-k-r-w-w-r-r, and the sequence is shown in the description. All amino acids are D-type amino acids; the antibacterial peptide can be used as an antibacterial substance in wash supplies, food preservative additives, medical consumable antibacterial agents and cosmetics, can be synthesized through an Fmoc solid-phase chemical method, and is low in synthesis difficulty and good in in-vivo antibacterial activity. Particularly, the antibacterial peptide has broad-spectrum killing activity against carbapenem pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the cell survival rate of the antibacterial peptide within the range of medium and low concentration (2 mu g / mL-32 mu g / mL) reaches half or more, the toxicity is small, the toxicity is almost avoided, the operability is high, and the antibacterial peptide can be widely applied to the field of medical application. The cost is low.

The invention belongs to the technical field of microorganisms, and particularly relates to application of parabacteroides dielsii SYSU-210 and metabolites thereof in cancer treatment. The parabacteroides dieldrii is a parabacteroides dieldrii SYSU-210 strain, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32494, and the preservation date is November 04, 2024. According to the application disclosed by the invention, by carrying out anti-tumor treatment on tumor-bearing mice with colon cancer and breast cancer by using the single parabacteroides dieldrii SYSU-210 and a metabolite thereof, the screened SYSU-210 has a good treatment effect on both the colon cancer and the breast cancer, and effector T cell infiltration in tumors of the mice in a treatment group is remarkably increased; and when the compound is combined with an immunotherapy alpha PD-1 inhibitor or a chemotherapeutic drug oxaliplatin for use, the effect of synergistically enhancing the curative effect is shown.

The invention discloses a polypeptide derived from deep sea microorganisms, and belongs to the technical field of peptide inhibitors. The polypeptide has an amino acid sequence as shown in SEQ ID NO: 1; the polypeptide has a bacteriostatic and / or bactericidal function. The polypeptide can inhibit the growth of acinetobacter baumannii at 8 [mu] M and inhibit the growth of escherichia coli and multi-drug-resistant acinetobacter baumannii at 16 [mu] M, and can be used for preparing products with bacteriostatic and / or bactericidal performance, such as food, daily necessities or medical products.

A Bifidobacterium longum subsp. infantis YLGB-1496 postbiotic product, a bacteriocin, a preparation method, and a use, specifically relating to the technical field of probiotic postbiotics. The provided probiotic postbiotic product has the following biological functions: enhancing the intestinal barrier function, preventing and / or treating inflammatory bowel diseases, regulating gut flora, relieving intestinal flatulence and resisting oxidation, and has application prospects in preparing health-care foods or drugs for regulating gut flora and resisting oxidation.

The invention relates to the technical field of microorganisms, in particular to bifidobacterium bifidum BGLP1 capable of regulating sugar digestion and producing GLP-1 at high yield and application of the bifidobacterium bifidum BGLP1. The preservation number of the bifidobacterium bifidum BGLP1 is CGMCC (China General Microbiological Culture Collection Center) No.35718, and the bifidobacterium bifidum BGLP1 can be used for preparing the feed additive. The strain has the capability of inhibiting alpha-glucosidase and alpha-amylase; sTC-1 cells are stimulated to secrete GLP-1, and the blood glucose reducing pathway capacity of the intestinal tract is activated; the activity of pancreatic lipase is obviously inhibited, and the dietary fat absorption capability can be effectively reduced; redundant cane sugar is converted into exopolysaccharide, so that the probiotic function capability is improved; the capability of converting white fat into brown fat is promoted; macrophages are activated, and the body immune function is improved. In addition, the bifidobacterium bifidum BGLP1 also has relatively strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can smoothly reach the intestinal tract of a human body.

The invention relates to a brand-new microbial natural metabolite, namely Fcl-8, which is derived from a fermentation solution of Xenorhabdius budapestensis XBD8, and is characterized in that the Fcl-8 is a new microbial natural metabolite, namely Fcl-8, which is derived from the fermentation solution of the Xenorhabdius budapestensis XBD8. The purified Fcl-8 is a snow white flocculent crystal and is very easy to dissolve in water, and the solid state of the purified Fcl-8 is as shown in Figure 1. The chemical structural formula of the Fcl-8 is as shown in a figure 2, the chemical formula is C57H102N14O12, the molecular weight is 1175.78744, and the typical secondary mass spectrum information of the Fcl-8 is as shown in a figure 3. The Fcl-8 is derived from a microbial natural metabolite, is novel in structure and high in biological activity, and has very high potential to be developed into a novel biopesticide.

The invention belongs to the technical field of bioengineering, and particularly relates to a sucrose phosphorylase mutant and application thereof in synthesis of 2-O-alpha-D-glucopyranosyl-L-ascorbic acid. The sucrose phosphorylase mutant is obtained by simultaneously mutating multiple sites of amino acids at the 91st site, the 154th site, the 185th site, the 323rd site and the 424th site of wild sucrose phosphorylase derived from Bifidobacterium pseudolongum, so that the efficiency of producing 2-O-alpha-D-glucopyranosyl-L-ascorbic acid by taking sucrose and vitamin C as raw materials is remarkably improved; only 15 hours are needed for completely catalyzing 1.2 M of vitamin C to produce 2-O-alpha-D-glucopyranosyl-L-ascorbic acid; and the yield of the 2-O-alpha-D-glucopyranosyl-L-ascorbic acid reaches 358 g / L. Therefore, the 2-O-alpha-D-glucopyranosyl-L-ascorbic acid has an important application value in the field of production of the 2-O-alpha-D-

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mh-GC21 as well as a precursor and application thereof. The amino acid sequence of the antibacterial peptide Mh-GC21 provided by the invention is as shown in SEQ ID NO.1, and two cysteines are oxidized to form a pair of intermolecular disulfide bonds; the C tail end of the antibacterial peptide Mh-GC21 is subjected to amidation modification. The antibacterial peptide Mh-GC21 provided by the invention is from microhyla microcarpa, has broad-spectrum antibacterial activity, has relatively good antibacterial and bactericidal effects on standard strains of acinetobacter baumannii, escherichia coli and staphylococcus aureus and clinically sourced drug-resistant strains, and can be used for targeted destruction of cell membranes of bacteria, removal of biological membranes and inhibition of formation of the biological membranes. Moreover, the antibacterial peptide Mh-GC21 has the advantages of good stability, no hemolytic activity and cytotoxicity, and difficulty in inducing strains to generate drug resistance.

The invention relates to the technical field of microorganisms, and particularly discloses bifidobacterium adolescentis AGE17 capable of promoting growth and development of muscles and bones and application of the bifidobacterium adolescentis AGE17. The bifidobacterium adolescentis AGE17 is separated from excrement of healthy children and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.33452, and the preservation date is January 17, 2025. The bifidobacterium adolescentis AGE17 has the advantages that the bifidobacterium adolescentis AGE17 can be used for preparing the biological organic fertilizer; animal experiments prove that the bifidobacterium adolescentis strain AGE17 provided by the invention has the function of promoting muscle and skeletal development, has more obvious and prominent effects compared with a model strain bifidobacterium adolescentis ATCC15703, and has important application value in increasing the muscle strength and height of children and adolescents.

The invention discloses bifidobacterium breve BBr26 capable of inhibiting hyaluronidase activity and relieving allergy as well as an application, a product and a method of the bifidobacterium breve BBr26, and belongs to the technical field of microorganisms. The invention provides a Bifidobacterium breve (Bifidobacterium breve) strain BBr26 with anti-allergy and / or immunoregulation capability, and the preservation number of the Bifidobacterium breve strain BBr26 is CGMCC (China General Microbiological Culture Collection Center) NO.32424. The invention also provides a preparation method of the Bifidobacterium breve strain The invention also provides an application of the strain bifidobacterium breve BBr26 in preparation of products for relieving atopic dermatitis, and / or food for enhancing immune function, and / or bacteriostatic agents, and a product and a method based on the strain BBr26. The strain disclosed by the invention has broad-spectrum bacteriostasis, can relieve allergy and atopic dermatitis, and can effectively play a role in immunoregulation.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention discloses bifidobacterium longum subsp. Infantis BIN31 for regulating immunity as well as application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a bifidobacterium longum subsp. Infantis BIN31, the preservation number of which is CGMCC (China General Microbiological Culture Collection Center) No. 33422, and the preservation number of the bifidobacterium longum subsp. Infantis BIN31 is CGMCC No. 33422. The invention also provides an application of the strain in preparation of food for enhancing immune function, and / or food with an auxiliary protection function on intestinal barrier, and / or food for regulating intestinal flora function, and / or a bacteriostatic agent, and also provides an application of the strain in preparation of food for enhancing immune function, and / or food with an auxiliary protection function on intestinal barrier, and / or food for regulating intestinal flora function. The invention also discloses a bacteriostatic agent and an in-vitro bacteriostatic method based on the strain, which have the functions of enhancing immune function, assisting in protecting intestinal barriers and regulating intestinal flora. The bifidobacterium longum subsp. Infantis BIN31 disclosed by the invention can effectively assist in protecting intestinal barriers, regulating intestinal flora, enhancing immunity and realizing broad-spectrum bacteriostasis.

The invention discloses a bifidobacterium animalis subsp. Animalis AN-YQ56 with the effects of inhibiting four highs and improving sleep quality, a metabiotic microbial inoculum, a preparation method and application of the bifidobacterium animalis subsp. Animalis AN-YQ56 and the metabiotic microbial inoculum. The strain is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC NO: M 20241567, the strain is classified and named as Bifidobacterium animalis subspecies AN-YQ56 Bifidobacterium animalis subsp.animalis AN-YQ56, and the preservation date is July 22, 2024, and the preservation number is CCTCC NO: M 20241567. No matter the strain AN-YQ56 is in a viable or inactivated state, body metabolism can be improved, diseases related to organs such as heart and cerebral vessels, livers and kidneys can be reduced, and occurrence of four highs can be effectively inhibited.